Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System

Jahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, Oliver Charles Cohen, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Amy A Kirkwood, Ashutosh D. Wechalekar

Blood (2024) 144 (Supplement 1): 890.

https://doi.org/10.1182/blood-2024-203527

Published: 2024

Journal Articles

Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis

Jahanzaib Khwaja, Sriram Ravichandran, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Shirley D'Sa, Ashutosh D. Wechalekar

Blood (2024) 144 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2024-207522

Published: 2024

Journal Articles

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

Blood (2024) 143 (13): 1259–1268.

https://doi.org/10.1182/blood.2023022399

Published: 2024

Includes: Supplemental data

Journal Articles

Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients

Jahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, Oliver Charles Cohen, Darren Foard, Ana Martinez - Naharro, Lucia Venneri, Marianna Fontana, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Carol Whelan, Ashutosh D. Wechalekar

Blood (2023) 142 (Supplement 1): 537.

https://doi.org/10.1182/blood-2023-178243

Published: 2023

Journal Articles

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Blood (2022) 140 (Supplement 1): 2351–2353.

https://doi.org/10.1182/blood-2022-160018

Published: 2022

Journal Articles

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood (2021) 138 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2021-149594

Published: 2021

Journal Articles

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood (2021) 138 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2021-149222

Published: 2021

Journal Articles

The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis

Oliver C Cohen, MBBS, BSc, FRCPath, Ananth Sathyanath, Sriram Ravichandran, MBBS, MRCP, FRCPath, Steven Law, MBBS, BSc, Richa Manwani, MBBS, FRCPath, BSc, Darren Foard, Sajitha Sachchithanantham, MBBS, BSc, FRCPath, Shameem Mahmood, Ana Martinez-Naharro, Marianna Fontana, Carol Whelan, Philip N Hawkins, Helen J Lachmann, Julian D Gillmore, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137036

Published: 2020

Journal Articles

The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis

Oliver C Cohen, MBBS, BSc, FRCPath, Andreia Ismael, Richa Manwani, MBBS, FRCPath, BSc, Sriram Ravichandran, MBBS, MRCP, FRCPath, Steven Law, MBBS, BSc, Darren Foard, Ana Martinez-Naharro, Shameem Mahmood, Sajitha Sachchithananthan, Philip N Hawkins, Helen J Lachmann, Julian D Gillmore, Marianna Fontana, Rodney H Falk, MD, Carol Whelan, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-137391

Published: 2020

Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (25): 2271–2280.

https://doi.org/10.1182/blood.2019000834

Published: 2019

Journal Articles

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Darren Foard, Faye Sharpley, Tamer Rezk, Thirusha Lane, Cristina Quarta, Marianna Fontana, Helen J. Lachmann, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (7): 761–764.

https://doi.org/10.1182/blood-2018-04-846493

Published: 2018

Journal Articles

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Blood (2017) 130 (Supplement 1): 1815.

https://doi.org/10.1182/blood.V130.Suppl_1.1815.1815

Published: 2017

Journal Articles

Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study

Richa Manwani, MBBS, FRCPath, BSc, Darren Foard, Shameem Mahmood, Sajitha Sachchithanantham, BSc,FRCPath,MBBS,MRCP, Marianna Fontana, Carol Whelan, Candida Quarta, Thirusha Lane, Helen Lachmann, Julian Gillmore, Philip Hawkins, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2017) 130 (Supplement 1): 1816.

https://doi.org/10.1182/blood.V130.Suppl_1.1816.1816

Published: 2017

Journal Articles

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

Ashutosh Wechalekar, MD FRCPath, Darren Foard, Carol Whelan, MD FRCP, Mariana Fontana, Thirusha Lane, RN MSc, Candida Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MD FRCP, Julian D Gillmore, MD PhD FRCP, Philip N Hawkins, MD PhD FMedSci

Blood (2016) 128 (22): 4511.

https://doi.org/10.1182/blood.V128.22.4511.4511

Published: 2016

Journal Articles

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Belen Sevillano, Haematology Specialist, Ashutosh Wechalekar, MDFRCPath FRCP, Darren Foard, Specialist Nurse, Carol Whelan, MDFRCP, Marianna Fontana, MD, Cristina Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MDFRCP, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 5357.

https://doi.org/10.1182/blood.V126.23.5357.5357

Published: 2015

Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci

Blood (2014) 124 (21): 3485.

https://doi.org/10.1182/blood.V124.21.3485.3485

Published: 2014

Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 1981.

https://doi.org/10.1182/blood.V122.21.1981.1981

Published: 2013

Journal Articles

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, MRCP, FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3120.

https://doi.org/10.1182/blood.V122.21.3120.3120

Published: 2013

Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3143.

https://doi.org/10.1182/blood.V122.21.3143.3143

Published: 2013

Journal Articles

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

Ashutosh D. Wechalekar, Stefan O. Schonland, Efstathios Kastritis, Julian D. Gillmore, Meletios A. Dimopoulos, Thirusha Lane, Andrea Foli, Darren Foard, Paolo Milani, Lisa Rannigan, Ute Hegenbart, Philip N. Hawkins, Giampaolo Merlini, Giovanni Palladini

Blood (2013) 121 (17): 3420–3427.

https://doi.org/10.1182/blood-2012-12-473066

Published: 2013

NARROW

Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System

Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis

The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only